FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 881 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR For People with Cancer, Are Steroids the Best Treatment for Breathing... October 25, 2022 Our new strategy to make discoveries, drive progress, and bring hope March 17, 2022 Mobile Care Center Brings Breast Cancer Treatment to Amish and Mennonite... December 18, 2019 EMA Recommends Refusal of the Marketing Authorisation for Pexidartinib July 3, 2020 Load more HOT NEWS We have a Deal: What does the new UK-EU relationship mean... Catch-Up HPV Testing May Help Prevent Cervical Cancer in Some Over... Reflecting on COVID-19 and the Importance of Providing Information to People... Working Outdoors in the Sunshine May Lower Your Risk of Breast...
